Nine Alliance Science & Technology Group

Nine Alliance Science & Technology Group

JMKJ
Nine Alliance Science & Technology GroupUS flagOther OTC
5.00
USD
- -
- -
1.13BMarket Cap
No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChat
CEO
Joseph C. Passalaqua
Sector
Consumer Cyclical
Industry
Apparel - Footwear & Accessories
Address
7325 Oswego Road Liverpool NY United States of America 13090
IPO Date
Aug 3, 2017
Business
Nine Alliance Science & Technology Group (JMKJ) operates as a holding company focused on innovative manufacturing and technology solutions in the industrial sector; it provides analytical services, chemical analysis, and technical support across chemical, pharmaceutical, and industrial segments. Core offerings encompass full-service laboratory testing with state-of-the-art instrumentation; expertise in phosphate, peroxygen, lithium, detergent, water treatment, and semiconductor chemicals; R&D method development; process technology; pharmaceutical testing; polymer chemistry; materials engineering; and inorganic chemistry analysis for chemical, specialty chemical, and pharmaceutical clients worldwide. Founded in 2014 and headquartered in Liverpool, New York, the company, formerly known as Paramount Supply Inc., rebranded to Coretag Holdings Inc. in recent years to emphasize its necrosis-targeting platform technology and targeted radiotherapy for cancer treatment; it maintains operations on OTC markets with recent address changes and quarterly earnings reports reflecting ongoing strategic shifts in Q2 and Q3 2024.